- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics Corp stock price live, this page displays NASDAQ SLXN stock exchange data. View the SLXN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Silexion Therapeutics Corp real time stock price chart below.
What Is the Silexion Therapeutics Corp Stock Price Today?
The Silexion Therapeutics Corp stock price today is 2.030.
What Is the Stock Symbol for Silexion Therapeutics Corp?
The stock symbol for Silexion Therapeutics Corp is "SLXN."
What Stock Exchange Does Silexion Therapeutics Corp Trade On?
Silexion Therapeutics Corp is listed and trades on the NASDAQ stock exchange.
Is Silexion Therapeutics Corp a Good Stock to Buy?
Determining whether Silexion Therapeutics Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SLXN quote. (ISIN: KYG1281K1307)
What Is the Silexion Therapeutics Corp Stock Price Today?
The Silexion Therapeutics Corp stock price today is 2.030.
What Is the Stock Symbol for Silexion Therapeutics Corp?
The stock symbol for Silexion Therapeutics Corp is "SLXN."
What Stock Exchange Does Silexion Therapeutics Corp Trade On?
Silexion Therapeutics Corp is listed and trades on the NASDAQ stock exchange.
Is Silexion Therapeutics Corp a Good Stock to Buy?
Determining whether Silexion Therapeutics Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SLXN quote. (ISIN: KYG1281K1307)
NASDAQ
Currency in USD
2.030
-0.040(-1.93%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.020
2.090
52 wk Range
1.650
51.750
SLXN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.0202.090
52 wk Range
1.65051.750
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SLXN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
9.000
Upside
+343.35%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Silexion Therapeutics Corp Company Profile
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Compare SLXN to Peers and Sector
Metrics to compare | SLXN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLXNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | 8.0x | −0.6x | |
PEG Ratio | −0.01 | −0.05 | 0.00 | |
Price/Book | 0.9x | 2.8x | 2.6x | |
Price / LTM Sales | - | 1.6x | 3.4x | |
Upside (Analyst Target) | 330.6% | 525.0% | 42.5% | |
Fair Value Upside | Unlock | 17.1% | 5.0% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 9.000
(+343.35% Upside)
Earnings
Latest Release
Nov 12, 2025
EPS / Forecast
-2.88 / -0.25
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Silexion Therapeutics (SLXN) Stock Price Today?
The Silexion Therapeutics stock price today is 2.030
What Stock Exchange Does Silexion Therapeutics Trade On?
Silexion Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Silexion Therapeutics?
The stock symbol for Silexion Therapeutics is "SLXN."
What Is the Silexion Therapeutics Market Cap?
As of today, Silexion Therapeutics market cap is 6.35M.
What Is Silexion Therapeutics's Earnings Per Share (TTM)?
The Silexion Therapeutics EPS (TTM) is -16.23.
From a Technical Analysis Perspective, Is SLXN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Silexion Therapeutics Stock Split?
Silexion Therapeutics has split 2 times.
How Many Employees Does Silexion Therapeutics Have?
Silexion Therapeutics has 13 employees.
What is the current trading status of Silexion Therapeutics (SLXN)?
As of Jan 28, 2026, Silexion Therapeutics (SLXN) is trading at a price of 2.030, with a previous close of 2.090. The stock has fluctuated within a day range of 2.020 to 2.090, while its 52-week range spans from 1.650 to 51.750.
What Is Silexion Therapeutics (SLXN) Price Target According to Analysts?
The average 12-month price target for Silexion Therapeutics is USD9.000, with a high estimate of USD12 and a low estimate of USD6. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +343.35% Upside potential.
What Is the SLXN After Hours Price?
SLXN's last after hours stock price is 2.110, the stock has decreased by 0.020, or 0.960%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.